Dong Wha Pharmaceutical Co. Ltd. has defined histone-lysine N-methyltransferase EZH1 and/or EZH2 inhibitors reported to be useful for the treatment of cancer.
Ventyx Biosciences Inc. has identified 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of ulcerative colitis and pulmonary fibrosis.
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described androgen receptor antagonists and/or androgen receptor degradation inducers reported to be useful for the treatment of gastrointestinal disorders, osteoporosis and SARS-CoV-2 infection (COVID-19), as well as breast and castration-resistant prostate cancer.
Centre Hospitalier Regional Universitaire de Lille and Centre National de la Recherche Scientifique have patented norbornene analogues reported to be useful for the treatment of tuberculosis.
Chugai Pharmaceutical Co. Ltd. has divulged nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NRF2) activators reported to be useful for the treatment of neurodegenerative, pulmonary and renal diseases.
Fudan University and Shanghaitech University have developed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via linker. They are reported to be useful for the treatment of cancer, autoimmune disease, myelofibrosis, neurodegeneration, kidney fibrosis, transplant rejection, diabetes and cardiovascular disorders, among others.
Pyrrole fused-ring pyrazole compounds have been prepared by Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. and characterized as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Research at Merck KGaA has led to the development of substituted heterocycles acting as kinesin-like protein KIFC1 (HSET) inhibitors reported to be useful for the treatment of cancer.
RSS
